# A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

> **NCT05483439** · PHASE2 · UNKNOWN · sponsor: **Shengjing Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Stage II-III Breast Cancer

## Interventions

- **DRUG:** cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
- **DRUG:** anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab)
- **DRUG:** traditional herbal medicine

## Key facts

- **NCT ID:** NCT05483439
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-20
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05483439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05483439, "A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05483439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*